SRT 3025 (hydrochloride)

SRT 3025 is an activator of sirtuin 1 (SIRT1).^1,2,3 It increases SIRT1 levels in, and inhibits RANKL-induced osteoclastogenesis of, mouse bone marrow-derived macrophages (BMDMs) when used at a concentration of 2 µM.¹ SRT 3025 inhibits the proliferation of SU.86.86 pancreatic adenocarcinoma cells (IC₅₀ = 0.98 µM).² It decreases plasma levels of LDL, VLDL, and total cholesterol in ApoE^-/- mice fed a high-cholesterol diet when administered at a dose of 3.18 g/kg.³

WARNING This product is not for human or veterinary use.

1. Gurt, I., Artsi, H., Cohen-Kfir, E., et al. The Sirt1 activators SRT2183 and SRT3025 Inhibit RANKL-induced osteoclastogenesis in bone marrow-derived macrophages and down-regulate Sirt3 in Sirt1 null cells. PLoS One 10(7), e0134391 (2015).

2. Chini, C.C.S., Espindola-Netto, J.M., Mondal, G., et al. SIRT1-activating compounds (STAC) negatively regulate pancreatic cancer cell growth and viability through a SIRT1 lysosomal-dependent pathway. Clin. Cancer Res. 22(10), 2496-2507 (2015).

3. Miranda, M.X., van Tits, L.J., Lohmann, C., et al. The Sirt1 activator SRT3025 provides atheroprotection in Apoe-/- mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. Eur. Heart J. 36(1), 51-59 (2015).